8-K: Esperion Acquires Corstasis, Expands Cardiovascular Portfolio

Esperion Therapeutics has entered a definitive agreement to acquire Corstasis Therapeutics for $75 million upfront, gaining FDA-approved Enbumyst and expanding its cardiovascular franchise.

Summary

• Esperion Therapeutics, Inc. (Esperion) will acquire Corstasis Therapeutics Inc. (Corstasis) through a merger, making Corstasis a wholly-owned subsidiary.
• The upfront cash consideration for the acquisition is $75,000,000, subject to customary adjustments.
• Corstasis equityholders are eligible for up to an additional $180,000,000 in milestone payments tied to regulatory approvals and commercial sales achievements.
• Equityholders will also receive low double-digit royalties on worldwide sales of Enbumyst and any follow-on products.
• The acquisition is expected to close in the second quarter of 2026.
• Esperion will finance the acquisition using existing credit facilities and royalty monetization of its Japanese royalties with funds managed by Athyrium Capital Management and HealthCare Royalty.
• Enbumyst (bumetanide nasal spray) is the first and only FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure (CHF), hepatic, and renal disease in adults, approved in September 2025.
• Corstasis is also advancing a sub-cutaneous pipeline, including a multidose pen injector, which could unlock additional market opportunities.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong strategic move, significantly enhancing Esperion's product pipeline and market position with a novel, FDA-approved therapy targeting a large unmet need. The financial structure appears prudent, balancing upfront costs with performance-based payments.

Positives

• Acquisition of Enbumyst, the first and only FDA-approved nasal spray loop diuretic for edema associated with CHF, hepatic, and renal disease, provides a differentiated, self-administered outpatient therapy.
• The transaction accelerates Esperion's momentum and advances its long-term Vision 2040, strengthening its leadership in cardiovascular care.
• Enbumyst is expected to leverage Esperion's established cardiovascular commercial infrastructure, synergistically expanding its product portfolio and accelerating double-digit revenue growth.
• The product targets a U.S. market with a potential opportunity exceeding $4 billion, with ability to expand across hepatic and renal indications including nephrotic syndrome.
• Corstasis's sub-cutaneous pipeline, including a multidose pen injector, offers potential for additional market opportunities.

Negatives

• The acquisition involves significant upfront cash payment and potential future milestone and royalty obligations, which could impact Esperion's financial liquidity and future earnings if Enbumyst sales do not meet expectations.
• Integration risks associated with acquiring a new company and product line, including potential challenges in combining commercial platforms and operational processes.

Risks

• Failure to consummate the Corstasis transaction.
• Failure to achieve anticipated sales of Enbumyst.
• Uncertainties regarding the net sales, profitability, and growth of Esperion's commercial products.
• Risks associated with clinical activities and results for current and future product candidates.
• Challenges related to supply chain, commercial development, and launch plans.
• Risks in business development activities.
• Uncertain outcomes and anticipated benefits of legal proceedings and settlements.
• General risks detailed in Esperion's filings with the Securities and Exchange Commission.

Future Outlook

Esperion anticipates that the acquisition will accelerate its momentum and advance its Vision 2040, driving sustained double-digit revenue growth and strengthening its leadership in cardiovascular care. The company plans to submit a Supplemental New Drug Application for Enbumyst and expects to unlock additional market opportunities through Corstasis's sub-cutaneous pipeline.

Management Comments

• Sheldon Koenig, President and CEO of Esperion: "This acquisition represents a compelling and strategically aligned opportunity that accelerates Esperion's momentum and advances our long-term Vision 2040. Enbumyst brings meaningful innovation to millions of patients who continue to struggle with the daily burden of diuretic therapy. Enbumyst's novel intranasal delivery, established regulatory approval, and expanding clinical footprint make it a natural fit for our cardiovascular franchise. We expect that by integrating Enbumyst into our proven commercial platform, we will drive sustained double-digit growth, strengthen our leadership in cardiovascular care, and create durable value for all of our stakeholders from patients and providers to employees and shareholders."
• Ben Esque, CEO of Corstasis Therapeutics: "Enbumyst was purpose-built in partnership with the cardiology community to address a clear unmet need. Today's acquisition validates our team's vision and approach. We are excited about the future of Enbumyst in Esperion's hands and its ability to intervene in the patient setting to treat worsening heart failure at home."
• James Udelson, MD, Chief of Cardiology, Tufts Medical Center: "The availability of an FDA-approved intranasal diuretic like Enbumyst represents an important therapeutic advance. Its novel intranasal delivery route offers the potential for more flexible, rapid, and patient-friendly fluid management that can be done at home precisely the kind of innovation we need to better support patients across the spectrum of cardiovascular and renal disease, and hopefully avoid the need for hospitalization."

Industry Context

StockSavvy.ai notes that this acquisition positions Esperion to capitalize on the growing demand for innovative cardiovascular and renal disease treatments, particularly for conditions like congestive heart failure where current oral diuretic options have limitations. The entry of a novel intranasal delivery system like Enbumyst could disrupt the market by offering a more convenient and potentially faster-acting alternative, aligning with broader industry trends towards patient-centric, home-based care solutions. This move also diversifies Esperion's portfolio beyond its existing non-statin LDL-C therapies, enhancing its competitive stance against larger pharmaceutical players in the cardiometabolic space.

Comparison to Industry Standards

• The upfront payment of $75 million and potential $180 million in milestones for a newly FDA-approved, first-in-class product targeting a multi-billion dollar market opportunity appears to be a reasonable valuation in the biopharmaceutical industry for a commercial-stage asset with significant growth potential. For example, similar acquisitions of novel therapies in cardiovascular or rare disease spaces often involve tiered payments linked to regulatory and commercial success.
• The low double-digit royalty structure is standard for such agreements, balancing risk and reward for both the acquirer and the selling shareholders.
• Esperion's strategy to leverage its existing commercial infrastructure for Enbumyst is a common industry practice aimed at maximizing efficiency and accelerating market penetration, similar to how companies like Amgen or Novartis integrate new assets into their established sales forces for related therapeutic areas.

Management Changes

Corporate Governance

Stakeholder Impact

• Corstasis Shareholders: Will receive an upfront cash payment of $75 million, plus potential milestone payments up to $180 million and low double-digit royalties on future sales, providing a significant return on their investment.
• Esperion Shareholders: Expected to benefit from accelerated double-digit revenue growth, expansion of the cardiovascular franchise, and creation of durable value through the acquisition of a novel, FDA-approved product with a large market opportunity.
• Patients: Will gain access to Enbumyst, a differentiated, self-administered outpatient diuretic therapy for edema associated with CHF, hepatic, and renal disease, potentially offering more flexible and patient-friendly fluid management at home.
• Employees (Corstasis): The merger agreement mentions resignations of Corstasis's board and officers, implying integration into Esperion's structure. Future employment status for other employees is not explicitly detailed but is implied by the acquisition.
• Customers/Providers: Healthcare providers will have a new therapeutic option (Enbumyst) for managing edema, potentially improving patient outcomes and reducing hospitalizations.

Next Steps

• The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions.
• Esperion will integrate Enbumyst into its commercial platform.
• Esperion plans to submit a Supplemental New Drug Application for Enbumyst.
• Corstasis's sub-cutaneous pipeline, including a multidose pen injector, will be advanced to unlock additional market opportunities.
• Esperion will host an investor conference call on March 3, 2026, at 8:00 a.m. ET to discuss the transactions.

Key Dates

Recommendation

The acquisition of Corstasis and its FDA-approved product, Enbumyst, represents a highly strategic and accretive move for Esperion. Enbumyst is a first-in-class therapy addressing a significant unmet need in a multi-billion dollar market, offering a differentiated delivery mechanism. This expands Esperion's core cardiovascular franchise, leverages its existing commercial infrastructure, and is projected to drive double-digit revenue growth, aligning with the company's long-term strategic vision. The financing structure, combining existing credit and royalty monetization, appears prudent. This transaction significantly enhances Esperion's growth prospects and market position, making it an attractive investment.

Keywords

Esperion Therapeutics, Corstasis Therapeutics, Merger Agreement, Acquisition, Enbumyst, Bumetanide Nasal Spray, Congestive Heart Failure, Edema Treatment, Cardiovascular Disease, Biopharmaceutical, FDA Approved, Loop Diuretic, Hepatic Disease, Renal Disease, Milestone Payments, Royalties, ESPR, Pharmaceutical Acquisition